Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
Category: Invir.IO
Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
20211109 – Transgene BioInvent SITC BT-001 en
Transgene Participates in New Cancer Research Consortium
Transgene Participates in New Cancer Research Consortium
Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)
20210608 – IP Invir.IO ICI – EN
Transgene and BioInvent receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors
210527 – Transgene BioInvent_BT001 IND_EN
Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas
K. Bendjama et al. AACR 2021 Read the abstract here – Download the poster here Poster Presentation
Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences
20210302 – Transgene Scientific Conferences
Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
20210301 – Transgene BT-001 FPI – EN
Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors
20210119 – ANSM Approval BT-001 EN
Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors
20201221 – CTA Approval BT-001 – EN